Abpro (ABP) Competitors $0.25 0.00 (-0.12%) As of 05/21/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ABP vs. KPTI, CNTB, QNCX, PLUR, AADI, ANEB, AVTX, ATRA, NRXP, and OSTXShould you be buying Abpro stock or one of its competitors? The main competitors of Abpro include Karyopharm Therapeutics (KPTI), Connect Biopharma (CNTB), Quince Therapeutics (QNCX), Pluri (PLUR), Aadi Bioscience (AADI), Anebulo Pharmaceuticals (ANEB), Avalo Therapeutics (AVTX), Atara Biotherapeutics (ATRA), NRx Pharmaceuticals (NRXP), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical products" industry. Abpro vs. Karyopharm Therapeutics Connect Biopharma Quince Therapeutics Pluri Aadi Bioscience Anebulo Pharmaceuticals Avalo Therapeutics Atara Biotherapeutics NRx Pharmaceuticals OS Therapies Karyopharm Therapeutics (NASDAQ:KPTI) and Abpro (NASDAQ:ABP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk. Do analysts rate KPTI or ABP? Karyopharm Therapeutics presently has a consensus price target of $43.20, indicating a potential upside of 819.15%. Abpro has a consensus price target of $4.00, indicating a potential upside of 1,471.09%. Given Abpro's higher possible upside, analysts plainly believe Abpro is more favorable than Karyopharm Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in KPTI or ABP? Karyopharm Therapeutics received 543 more outperform votes than Abpro when rated by MarketBeat users. However, 100.00% of users gave Abpro an outperform vote while only 72.44% of users gave Karyopharm Therapeutics an outperform vote. CompanyUnderperformOutperformKaryopharm TherapeuticsOutperform Votes54472.44% Underperform Votes20727.56% AbproOutperform Votes1100.00% Underperform VotesNo Votes Which has higher valuation and earnings, KPTI or ABP? Abpro has lower revenue, but higher earnings than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$142.13M0.29-$143.10M-$13.26-0.35Abpro$183K72.65N/AN/AN/A Does the media refer more to KPTI or ABP? In the previous week, Karyopharm Therapeutics had 5 more articles in the media than Abpro. MarketBeat recorded 8 mentions for Karyopharm Therapeutics and 3 mentions for Abpro. Abpro's average media sentiment score of 0.83 beat Karyopharm Therapeutics' score of 0.37 indicating that Abpro is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Abpro 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in KPTI or ABP? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Abpro shares are owned by institutional investors. 3.0% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 20.8% of Abpro shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is KPTI or ABP more profitable? Abpro has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-52.62% N/A -39.58% Abpro N/A N/A N/A Which has more volatility & risk, KPTI or ABP? Karyopharm Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Abpro has a beta of -0.01, indicating that its share price is 101% less volatile than the S&P 500. SummaryAbpro beats Karyopharm Therapeutics on 7 of the 13 factors compared between the two stocks. Get Abpro News Delivered to You Automatically Sign up to receive the latest news and ratings for ABP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABP vs. The Competition Export to ExcelMetricAbproHolding Offices IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.30M$478.20M$5.37B$8.39BDividend YieldN/A7.56%5.22%4.10%P/E RatioN/A2.5326.7719.71Price / Sales72.6559.24393.17117.39Price / CashN/A69.0138.2534.62Price / BookN/A6.846.794.50Net IncomeN/A$35.22M$3.23B$248.18M7 Day Performance-3.96%0.45%1.53%0.20%1 Month Performance-4.64%3.32%10.06%12.37%1 Year PerformanceN/A24.62%16.74%7.04% Abpro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABPAbproN/A$0.25-0.1%$4.00+1,471.1%N/A$13.30M$183,000.000.0015Earnings ReportGap DownKPTIKaryopharm Therapeutics3.8339 of 5 stars$4.92-20.0%$43.20+778.0%-72.0%$42.16M$145.24M-4.82380Gap DownHigh Trading VolumeCNTBConnect Biopharma3.2682 of 5 stars$0.76-5.2%$8.00+951.2%-54.0%$42.12M$26.03M0.00110Earnings ReportQNCXQuince Therapeutics2.895 of 5 stars$0.95-7.8%$8.00+742.1%+19.8%$41.92MN/A-0.7760PLURPluri0.4083 of 5 stars$5.35-0.4%N/A-25.8%$41.58M$678,000.00-0.96150AADIAadi Bioscience0.6706 of 5 stars$1.67-1.8%$1.67-0.2%+7.6%$41.24M$25.07M-0.7340ANEBAnebulo Pharmaceuticals2.2543 of 5 stars$0.98-0.5%$8.00+720.4%-49.8%$40.06MN/A-3.484AVTXAvalo Therapeutics3.4076 of 5 stars$3.68-8.0%$33.00+796.7%-65.3%$39.85M$441,000.000.0040Gap DownATRAAtara Biotherapeutics4.0811 of 5 stars$6.68+3.2%$17.75+165.7%-60.2%$39.82M$128.94M-0.26330News CoverageEarnings ReportGap DownNRXPNRx Pharmaceuticals1.9255 of 5 stars$2.29+10.1%$28.50+1,144.5%-31.9%$39.45MN/A-1.072Earnings ReportGap UpHigh Trading VolumeOSTXOS Therapies2.0506 of 5 stars$1.81+6.5%$18.00+894.5%N/A$39.21MN/A0.00N/A Related Companies and Tools Related Companies KPTI Alternatives CNTB Alternatives QNCX Alternatives PLUR Alternatives AADI Alternatives ANEB Alternatives AVTX Alternatives ATRA Alternatives NRXP Alternatives OSTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABP) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abpro Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abpro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
